1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,200 | 5,250 | 11:01 | |
| 5,150 | 5,350 | 06.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cytek Biosciences, Inc.: Cytek Aurora Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year | 4 | GlobeNewswire (USA) | ||
| Do | Cytek outlines $208M-$211M 2026 revenue range while postponing business unit rollout to 2027 | 1 | Seeking Alpha | ||
| Mi | Cytek Biosciences, Inc.: Cytek Biosciences Reports Third Quarter 2026 Financial Results | 2 | GlobeNewswire (USA) | ||
| Mi | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026 | 2 | GlobeNewswire (USA) | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.09. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.09. | Cytek Biosciences stellt cloudbasiertes Analyse-Tool vor | 1 | Investing.com Deutsch | ||
| 23.09. | Cytek Biosciences launches cloud-based analysis tool | 1 | Investing.com | ||
| 23.09. | Cytek Biosciences, Inc.: Cytek Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis Tool | 1 | GlobeNewswire (USA) | ||
| 17.09. | Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock? | 1 | Zacks | ||
| 16.09. | Cytek auf Morgan Stanley Konferenz: Wachstum gewinnt an Breite, Europe bleibt schwach | 1 | Investing.com Deutsch | ||
| 09.09. | Sysmex Europe SE and Cytek Biosciences, Inc. Collaborate to Expand Access to Advanced Clinical Flow Cytometry | 879 | GlobeNewswire (Europe) | FREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in spectral... ► Artikel lesen | |
| 09.09. | Cytek's (CTKB) Instruments Keep Selling While Losses Keep Growing | 4 | Insider Monkey | ||
| 03.09. | Cytek Biosciences, Inc.: Cytek Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS | 1 | GlobeNewswire (USA) | ||
| 24.08. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Cytek Biosciences: Teilsieg im Patentstreit - dennoch 56 Millionen US-Dollar Schadenersatz | 2 | Investing.com Deutsch | ||
| 21.08. | Cytek Biosciences wins on three of four patent claims | 3 | Investing.com | ||
| 21.08. | Cytek Biosciences, Inc.: Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding | 902 | GlobeNewswire (Europe) | FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (Nasdaq: CTKB), a leading cell analysis solutions company, today announced... ► Artikel lesen | |
| 12.08. | Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments | 2 | pulse2.com | ||
| 06.08. | Cytek raises 2026 revenue outlook to $207M-$212M as it rolls out Borealis and Aurora Evo automation | 2 | Seeking Alpha |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,003 | -5,56 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,890 | -4,30 % | Biofrontera AG: Was steckt hinter den Halbjahreszahlen? | ||
| CLINUVEL | 4,518 | -1,16 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| EDITAS MEDICINE | 2,270 | -1,73 % | Jones Trading initiates Editas Medicine stock coverage with buy rating | ||
| BIOCRYST PHARMACEUTICALS | 6,856 | -0,61 % | Biocryst outlines $415M-$425M 2026 operating expense guidance while keeping ORLADEYO at $625M-$645M | ||
| CARDIOL THERAPEUTICS | 0,844 | -4,63 % | Cardiol Therapeutics drops after launching a $75M ATM offering | ||
| ARBUTUS BIOPHARMA | 3,300 | +0,61 % | Arbutus Biopharma: FDA-Schritt hilft, aber der Chart bleibt unter Druck | ||
| ASEP MEDICAL | 0,104 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,270 | +1,60 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,662 | -7,29 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 0,570 | 0,00 % | H.C. Wainwright bestätigt Aldeyra-Aktie mit "Neutral" und Kursziel von 2 US-Dollar | ||
| DENALI THERAPEUTICS | 18,060 | +0,33 % | DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? | ||
| ABCELLERA BIOLOGICS | 10,560 | -1,12 % | AbCellera Biologics Inc.: AbCellera to Present at Upcoming Investor Conferences in November 2026 | AbCellera (Nasdaq: ABCL) announced thatthe Company will present at the following investor conferences:
Stifel Healthcare Conference, November 11, 2026
Jefferies Global Healthcare Conference... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 25,000 | -0,36 % | Adaptive Biotechnologies raises 2026 MRD revenue guide to $276M-$286M as it targets $1,700-$1,800 ASP | ||
| COHERUS ONCOLOGY | 0,669 | -3,11 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 30.09.2026 | Das Instrument PYXB GB00BP9LHF23 SCHRODERS PLC LS -,20 EQUITY wird cum Kapitalmassnahme gehandelt am 30.09.2026 und ex Kapitalmassnahme am 01.10.2026 The instrument PYXB GB00BP9LHF23 SCHRODERS PLC LS... ► Artikel lesen |
CYTEK BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,250 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.